Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Neuren Pharmaceuticals Ltd

Healthcare AU NEU

12.55AUD
-0.2(1.57%)

Last update at 2026-03-11T05:11:00Z

Day Range

12.4912.78
LowHigh

52 Week Range

8.6122.98
LowHigh

Fundamentals

  • Previous Close 12.75
  • Market Cap1564.00M
  • Volume424371
  • P/E Ratio53.70
  • Dividend Yield-%
  • EBITDA22.06M
  • Revenue TTM64.65M
  • Revenue Per Share TTM0.50
  • Gross Profit TTM 28.26M
  • Diluted EPS TTM0.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 38.93M 182.94M 205.14M 0.18M -7.79400M
Minority interest - - - - -
Net income 30.44M 142.04M 157.08M 2.37M -7.74500M
Selling general administrative - 4.70M 5.95M 3.44M 1.91M
Selling and marketing expenses - - 0.02M - -
Gross profit 64.61M 213.22M 205.17M 14.55M -
Reconciled depreciation - 0.02M 0.02M 0.01000M 0.00800M
Ebit 22.02M 175.55M 199.25M -1.60600M -11.43800M
Ebitda 22.05M 175.57M 199.26M -1.59600M -11.43000M
Depreciation and amortization 0.02M 0.02M 0.02M 0.01000M 0.00800M
Non operating income net other - - - - -
Operating income 22.02M 175.55M 172.49M -1.60600M -11.43800M
Other operating expenses 42.61M 37.69M 59.45M 16.16M 11.44M
Interest expense - - - 0.39M 3.64M
Tax provision - 40.90M 48.06M 0.00000M 0.00000M
Interest income - 11.01M 5.69M 0.39M 0.40M
Net interest income - 11.01M 5.69M 0.39M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 8.49M 40.90M 48.06M -2.18100M -0.04900M
Total revenue 64.63M 213.24M 231.93M 14.55M 0.04M
Total operating expenses 42.59M 37.67M 32.70M 16.16M 11.44M
Cost of revenue 0.02M 0.02M 26.75M - -
Total other income expense net 16.91M 7.39M 32.65M 1.79M 3.64M
Discontinued operations - - - - -
Net income from continuing ops - 142.04M 157.08M 0.18M -7.79400M
Net income applicable to common shares - 142.04M 157.08M 0.18M -7.79400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 342.86M 409.71M 247.97M 43.27M 40.06M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.57M 4.17M 4.21M 1.98M 1.84M
Total liab 4.41M 45.80M 42.76M 1.68M 0.80M
Total stockholder equity 338.45M 363.90M 205.21M 41.59M 39.25M
Deferred long term liab - - - - -
Other current liab 3.46M 44.31M 42.09M 1.42M 0.56M
Common stock 134.94M 165.27M 173.13M 167.74M 167.58M
Capital stock - - 173.13M 167.74M 167.58M
Retained earnings 210.87M 180.43M 38.39M -118.69300M -118.87700M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - -
Cash 4.23M 3.15M 17.09M 40.18M 36.78M
Cash and equivalents - - - 37.88M 29.87M
Total current liabilities 4.34M 45.76M 42.76M 1.68M 0.80M
Current deferred revenue - - - - -
Net debt -4.22700M -3.15300M -17.09400M -40.18000M -36.78300M
Short term debt - - - 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - 0.00000M - -10.68000M -9.44800M
Property plant equipment - - - 0.02M 0.01M
Total current assets 332.23M 399.33M 247.16M 43.25M 40.04M
Long term investments - - - - -
Net tangible assets - - - 41.59M 39.25M
Short term investments 291.89M 219.09M 211.44M - -
Net receivables 26.54M 172.91M 14.41M 1.09M 1.42M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.88M 1.45M 0.68M 0.26M 0.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -7.35700M 18.20M -6.30800M -7.45800M -9.44800M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 10.35M -0.00000M - -
Deferred long term asset charges - - - - -
Non current assets total 10.63M 10.38M 0.81M 0.02M 0.01M
Capital lease obligations - - - - -
Long term debt total - - - 0.00000M 0.00000M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 4.13M -211.48500M -0.01900M -0.01000M
Change to liabilities - - - 0.34M -0.11400M
Total cashflows from investing activities -88.00700M 4.13M -211.48500M -0.01900M -0.01000M
Net borrowings - - - - -
Total cash from financing activities -33.22100M -8.77500M 3.62M -0.00200M 22.18M
Change to operating activities - - - - -
Net income 30.44M 142.04M 157.08M 2.37M -7.79400M
Change in cash 1.07M -13.94100M -23.08600M 3.40M 12.60M
Begin period cash flow 3.15M 17.09M 40.18M 36.78M 24.19M
End period cash flow 4.23M 3.15M 17.09M 40.18M 36.78M
Total cash from operating activities 125.42M -11.27000M 184.93M 2.38M -9.97000M
Issuance of capital stock - 1.66M 3.64M - 23.28M
Depreciation 0.02M 0.02M 0.02M 0.01000M 0.00800M
Other cashflows from investing activities - 4.14M -211.44500M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 154.59M -157.10600M -15.55100M 0.19M -2.50600M
Sale purchase of stock -39.57300M -10.42600M -0.01800M -0.00200M -1.10600M
Other cashflows from financing activities - 1.65M -211.48500M -0.01900M -0.01000M
Change to netincome - - - 2.87M 0.44M
Capital expenditures 0.04M 0.01000M 0.04M 0.02M 0.01000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 96.02M -157.58500M 23.24M -1.23300M 0.82M
Stock based compensation - 1.23M 2.93M - -
Other non cash items -1.05700M 4.27M 7.52M -2.37500M 7.79M
Free cash flow 125.39M -11.28000M 184.88M 2.36M -9.98000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NEU
Neuren Pharmaceuticals Ltd		 -0.2 1.57% 12.55 53.70 45.66 24.19 4.61 19.56 57.40
CSL
CSL Ltd		 -1.98 1.37% 142.58 16.70 19.49 4.61 2.68 3.87 11.63
TLX
TELIX Pharmaceuticals Ltd		 -0.24 2.18% 10.76 - 1000.00 4.25 5.68 3.34 76.39
MSB
Mesoblast Ltd		 0.01 0.46% 2.19 - 454.55 43.02 3.19 28.08 -9.8623
PYC
PYC Therapeutics Ltd		 0.03 1.70% 1.50 - 12.00 68.69 9.50 25.02 -8.4071

Reports Covered

Stock Research & News

View All

Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Neuren Pharmaceuticals Ltd

117 Camberwell Road, Hawthorn East, VIC, Australia, 3123

Key Executives

Name Title Year Born
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons) CEO, MD & Director NA
Ms. Lauren Frazer C.A. CFO & Company Sec. NA
Mr. Lawrence Glass Chief Science Officer NA
Mr. Gerry Zhao VP of Corp. Devel. NA
Dr. Liza A. Squires M.D. Chief Medical Officer NA
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director NA
Ms. Lauren Frazer C.A. CFO & Company Secretary NA
Mr. Lawrence Glass BA (Biology) Chief Science Officer NA
Mr. Gerry Zhao Vice President of Corporate Development NA
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.